EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bausch & Lomb's Enterprise Value is C$15,585 Mil.
Bausch & Lomb's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was C$3 Mil. Therefore, Bausch & Lomb's EV-to-FCF for today is 5,524.62.
The historical rank and industry rank for Bausch & Lomb's EV-to-FCF or its related term are showing as below:
TSX:BLCO'
s EV-to-FCF Range Over the Past 10 Years
Min: -522.67 Med: -52.38 Max: 5524.62
Current: 5524.62
During the past 8 years, the highest EV-to-FCF of Bausch & Lomb was 5524.62. The lowest was -522.67. And the median was -52.38.
TSX:BLCO's EV-to-FCF is ranked worse than 99.76% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.515
vs TSX:BLCO: 5524.62
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bausch & Lomb's PE Ratio (TTM) for today is calculated as:
Bausch & Lomb's share price for today is C$24.31.
Bausch & Lomb's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.852.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bausch & Lomb EV-to-FCF Related Terms
Bausch & Lomb EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's EV-to-FCF falls into.
Bausch & Lomb's current Enterprise Value is C$15,585 Mil.
Bausch & Lomb's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (TSX:BLCO) has a EV-to-FCF of 5,524.62 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bausch & Lomb and its competitors. According to the industry distribution chart, Bausch & Lomb ranks #415 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 99.8%.
Is Bausch & Lomb's EV-to-FCF too high?
Bausch & Lomb's current EV-to-FCF is 5,524.62. The Medical Devices & Instruments industry median EV-to-FCF is 23.52. Bausch & Lomb's value of 5,524.62 is 23394% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #415 out of 416 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #415 out of 416 companies for EV-to-FCF. This places Bausch & Lomb in the lower half of its industry. The industry median EV-to-FCF is 23.52. Bausch & Lomb's value of 5,524.62 is 23394% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current EV-to-FCF of 5,524.62 is 23394% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current EV-to-FCF is 5,524.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (TSX:BLCO) is currently considered Fairly Valued. The stock's GF Value™ is C$26.19, compared to a current price of C$24.31 — trading 7.2% below its estimated fair value. The current EV-to-FCF is 5,524.62 and 23394% above the Medical Devices & Instruments industry median of 23.52. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bausch & Lomb (TSX:BLCO), the current EV-to-FCF is 5,524.62 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (TSX:BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of C$24.31 is trading 7.2% below its estimated GF Value™ of C$26.19.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for TSX:BLCO:
EV-to-FCF: 5,524.62
GF Value™: C$26.19 vs. price of C$24.31 (7.2% below fair value)
Industry Position: 23394% above the Medical Devices & Instruments median (#415 of 416)
No single metric tells the full story. See the TSX:BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for TSX:BLCO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:BLCO has been successfully added to your 
